Gene Therapy Lyfgenia denied as experimental or investigational by State Medicaid (varies)?

State Medicaid (varies)'s specific coverage criteria for gene therapy lyfgenia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why State Medicaid Programs Deny Lyfgenia as Experimental

An "experimental or investigational" denial means the Medicaid program or its managed care organization has classified Lyfgenia under a coverage policy that excludes therapies deemed not proven to be safe and effective for standard clinical use. This is a significant factual error: Lyfgenia received full FDA approval and is not an investigational or experimental therapy. The denial is almost certainly the result of an outdated coverage policy, a coverage database that has not been updated since approval, or a blanket gene-therapy exclusion that was written before gene therapies reached FDA approval.

State Medicaid programs are required under federal law (42 C.F.R. §440.230) to provide services in sufficient amount, duration, and scope to reasonably achieve the purpose for which the services are furnished. Denying an FDA-approved treatment for a serious condition as "experimental" when it is not experimental raises a direct federal compliance question.

## Why This Denial Is Appealable

FDA approval is the federal regulatory determination that a drug is safe and effective for its approved indication. An insurer's internal "experimental" classification cannot override that determination when the claim is for the FDA-approved use. Courts and external reviewers have consistently found that denials classifying FDA-approved drugs as experimental — when used for their approved indication — do not meet the required legal standard.

## Your Appeal Rights and Timeline

• State Medicaid fair hearing: Request a fair hearing immediately upon receipt of the denial. State deadlines vary — the denial notice must state the deadline.
• Expedited process: If the condition is urgent (active acute complications or deteriorating organ function), request an expedited fair hearing.
• Managed care external review: If coverage is through a Medicaid managed care organization, the plan may also offer or be required to offer independent external review.
• Federal complaint pathway: Denials of FDA-approved treatments for serious conditions may also be raised with the federal Centers for Medicare & Medicaid Services (CMS) through the state agency.

## Documentation to Gather

1. FDA approval documentation: Print the FDA product label and approval letter for Lyfgenia from the FDA website. Attach it to the appeal. 2. Diagnosis and indication confirmation: Records confirming the patient's sickle cell disease diagnosis matches the FDA-approved indication exactly. 3. Prescriber letter: The treating hematologist's letter confirming that the prescription is for the FDA-approved indication, not an off-label or investigational use. 4. Clinical guideline reference: A reference (without specific numbers) to the applicable professional society guidelines recognizing gene therapy as a treatment option for sickle cell disease — confirming it reflects current standard of care.

## Criteria-Mapping Structure

Obtain the Medicaid program's or managed care plan's coverage policy for Lyfgenia or its gene therapy coverage policy generally. Challenge each basis for the "experimental" classification:

| Claimed Experimental Basis | Rebuttal Evidence | |---|---| | Not FDA approved | FDA approval letter + prescribing label attached | | Insufficient evidence of efficacy | FDA approval review summary; guideline organization recognition | | Use is off-label | Prescriber letter confirming on-label, approved indication | | Policy not yet updated | Request policy update as part of appeal |

Include a clear, single-sentence statement at the top of the appeal letter: "This appeal concerns a claim for an FDA-approved therapy used for its FDA-approved indication. The 'experimental' classification is factually incorrect."